Perspectives
Insightful perspectives from the key opinion leaders shaping AI-driven drug discovery and development.
A curated board of perspectives from the scientists, founders, and executives defining how artificial intelligence is reshaping drug discovery and development. Each entry pairs a leader's core thesis with their own words and a link to the source.
Building on AlphaFold, Hassabis argues AI can turn a decade-long discovery process into something an order of magnitude faster, with AI-designed drugs heading toward the clinic. “We've got this amazing tool that could finally unlock some of the biggest mysteries around disease and help us overcome them” — framing the mission as nothing less than to “solve all disease.” Source: Fortune
The value of ML is not making scientists faster but making discovery itself more predictable — models trained on large, purpose-built biological datasets surface disease patterns humans can't see, raising the odds a drug actually works. “It will be a paradigm shift… we're entering a new era of science — we finally have enough data and technology to truly enable better drugs for patients.” Source: McKinsey
Co-discoverer of the AI-found antibiotic halicin, Barzilay pushes the field past brute-force screening: “A lot of AI use in drug discovery has been about searching chemical space, identifying new molecules that might be active — but AI can also provide mechanistic explanations, which are critical for moving a molecule through the development pipeline.” Source: MIT News
A pioneer of generative chemistry whose AI-designed candidates have reached the clinic, Zhavoronkov reframes who designs drugs: “We need to recognize medicinal chemists, even when some of those are not human.” He is also a realist on limits — without regulatory modernization, he warns, timelines are nearing how fast the current paradigm can go. Source: GEN
Now leading Recursion after its merger with Exscientia, Khan brings a results-first discipline to AI drug discovery: “The companies that are really going to be able to transition from promise to proof to product are going to be the ones that are the winners.” Her thesis on execution — “the magic comes from a culture where disciplines are treated as equal and integrated… from start to finish.” Source: STAT News
Huang casts biology as the next computing platform — learning the “language” of proteins and scaling simulation until drug design accelerates the way chip design once did. Digital biology, he argues, could be “one of the biggest revolutions ever,” turning biology “from a science into engineering.” Source: NVIDIA
Topol argues that demanding zero error from AI ignores the very real harm of human diagnostic error, and that multimodal AI can finally shift medicine from treatment toward earlier prediction and prevention — “a much different level of precision and accuracy medicine going forward.” A caution, too: nearly 1,000 FDA-cleared AI models exist, yet few are actually in use. Source: HCI
About this board. A hand-curated selection of public perspectives from recognized leaders in AI for drug discovery and development — paraphrased context plus direct quotes, each linked to its source. Quotes are reproduced from public interviews and articles and attributed to their authors; roles reflect positions as of June 2026. Suggestions for voices to add are welcome.
More of my own writing — including earlier technical posts — is in the blog archive, and the live AI in Pharma tracker aggregates daily news and commentary.